MedTrace Logo

The Efficacy and Safety of "BST104" (Lonicera Flos Extract) in Mild to Moderate Functional Dyspepsia Subjects

NCT04008901 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2023-04-18

No results posted yet for this study

Summary

This study was conducted to prove the efficacy of BST-104 in patients with mild to moderate FD.

Conditions

  • Functional Dyspepsia
  • Irritable Bowel Syndrome

Interventions

DRUG

BST-104 (Lonicera Flos Extract)

175 mg of Lonicera Flos extract in 1 tablet (300 mg)

DRUG

Placebo oral tablet

0 mg of Lonicera Flos extract in 1 tablet (300 mg)

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-13
Primary Completion
2018-07-02
Completion
2018-11-08

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04008901 on ClinicalTrials.gov